File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Human embryonic stem cell-derived cardiomyocytes for heart therapies

TitleHuman embryonic stem cell-derived cardiomyocytes for heart therapies
Authors
KeywordsHeart disease
Human embryonic stem cells
Issue Date2007
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cdtchd
Citation
Cardiovascular And Hematological Disorders - Drug Targets, 2007, v. 7 n. 2, p. 145-152 How to Cite?
AbstractCardiovascular diseases remain the leading cause of mortality and morbidity worldwide. Despite substantial improvements in acute management, survivors of myocardial infarction often progress to heart failure. Since adult cardiomyocytes (CMs) do not regenerate, their loss permanently compromises myocardial contractile function. Heart transplantation is currently the last resort for end-stage heart failure, but is hampered by a severe shortage of donor organs and rejection. Cell-based therapies are a promising alternative: Various cell types such as human fetal CMs, skeletal muscle myoblasts and smooth muscle cells have been tested but these approaches are also limited by cell availability or side effects (e.g. due to their non-cardiac identity). In recent years, clinical studies exploiting adult bone marrow mesenchymal stem cells for transplantation in patients with coronary artery disease have reported favorable outcomes but their cardiomyogenic ability is limited. By contrast, human embryonic stem cells (hESCs), derived from the inner cell mass of blastocyst-stage embryos, are pluripotent and can self-renew and differentiate into all cell types including CMs. Furthermore, hESC-derived CMs (hESC-CMs) are viable human heart cells that can functionally integrate with the recipient organ after transplantation. This article reviews the current state and hurdles of hESC-CM research, as well as their therapeutic potentials and limitations. © 2007 Bentham Science Publishers Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/91421
ISSN
2015 SCImago Journal Rankings: 0.718
References

 

DC FieldValueLanguage
dc.contributor.authorSiu, CWen_HK
dc.contributor.authorMoore, JCen_HK
dc.contributor.authorLi, RAen_HK
dc.date.accessioned2010-09-17T10:19:06Z-
dc.date.available2010-09-17T10:19:06Z-
dc.date.issued2007en_HK
dc.identifier.citationCardiovascular And Hematological Disorders - Drug Targets, 2007, v. 7 n. 2, p. 145-152en_HK
dc.identifier.issn1871-529Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/91421-
dc.description.abstractCardiovascular diseases remain the leading cause of mortality and morbidity worldwide. Despite substantial improvements in acute management, survivors of myocardial infarction often progress to heart failure. Since adult cardiomyocytes (CMs) do not regenerate, their loss permanently compromises myocardial contractile function. Heart transplantation is currently the last resort for end-stage heart failure, but is hampered by a severe shortage of donor organs and rejection. Cell-based therapies are a promising alternative: Various cell types such as human fetal CMs, skeletal muscle myoblasts and smooth muscle cells have been tested but these approaches are also limited by cell availability or side effects (e.g. due to their non-cardiac identity). In recent years, clinical studies exploiting adult bone marrow mesenchymal stem cells for transplantation in patients with coronary artery disease have reported favorable outcomes but their cardiomyogenic ability is limited. By contrast, human embryonic stem cells (hESCs), derived from the inner cell mass of blastocyst-stage embryos, are pluripotent and can self-renew and differentiate into all cell types including CMs. Furthermore, hESC-derived CMs (hESC-CMs) are viable human heart cells that can functionally integrate with the recipient organ after transplantation. This article reviews the current state and hurdles of hESC-CM research, as well as their therapeutic potentials and limitations. © 2007 Bentham Science Publishers Ltd.en_HK
dc.languageengen_HK
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cdtchden_HK
dc.relation.ispartofCardiovascular and Hematological Disorders - Drug Targetsen_HK
dc.subjectHeart diseaseen_HK
dc.subjectHuman embryonic stem cellsen_HK
dc.subject.meshCalcium - metabolism-
dc.subject.meshElectrophysiology-
dc.subject.meshEmbryonic Stem Cells - physiology - transplantation-
dc.subject.meshHeart Diseases - therapy-
dc.subject.meshMyocytes, Cardiac - physiology-
dc.titleHuman embryonic stem cell-derived cardiomyocytes for heart therapiesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1871-529X&volume=7&issue=2&spage=145&epage=152&date=2007&atitle=Human+embryonic+stem+cell-derived+cardiomyocytes+for+heart+therapies-
dc.identifier.emailSiu, CW:cwdsiu@hkucc.hku.hken_HK
dc.identifier.emailLi, RA:ronaldli@hkucc.hku.hken_HK
dc.identifier.authoritySiu, CW=rp00534en_HK
dc.identifier.authorityLi, RA=rp01352en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid17584049-
dc.identifier.scopuseid_2-s2.0-34347382201en_HK
dc.identifier.hkuros183047-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34347382201&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume7en_HK
dc.identifier.issue2en_HK
dc.identifier.spage145en_HK
dc.identifier.epage152en_HK
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridSiu, CW=7006550690en_HK
dc.identifier.scopusauthoridMoore, JC=35185459800en_HK
dc.identifier.scopusauthoridLi, RA=7404724466en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats